Welcome to our dedicated page for VRAY news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on VRAY stock.
ViewRay, Inc. (Nasdaq: VRAY) pioneers MRI-guided adaptive radiotherapy through its MRIdian® system, which enhances cancer treatment precision with real-time imaging and adaptive dosing. This page aggregates official announcements, financial updates, and clinical milestones for investors and healthcare professionals tracking advancements in radiation therapy technology.
Key resources include: Press releases on MRIdian® installations like the VA Oklahoma City partnership, earnings reports, regulatory clearances, and research collaborations. Stay informed on ViewRay's role in expanding access to non-invasive therapies that prioritize patient safety and outcomes.
Bookmark this page for streamlined access to verified updates about VRAY's innovations in medical technology. Visit regularly to monitor developments in MRI-guided treatment adoption and ViewRay's global impact on oncology care.
ViewRay, Inc. (NASDAQ: VRAY) announced the purchase of a MRIdian MRI-Guided Radiation Therapy System by Saitama Medical University International Medical Center for its cancer center in Hidaka-City, Japan. Scheduled for installation in December 2022, the system will enhance personalized treatments for various cancers, including those of the pancreas and prostate. This advanced technology allows for real-time tracking and automated beam gating, facilitating efficient treatment delivery. Saitama aims to participate in international research to further cancer treatment methodologies.
ViewRay, Inc. (Nasdaq: VRAY) will release its first quarter 2022 financial results on August 2, 2022, followed by a conference call at 4:30 p.m. ET. Investors can join via dial-in numbers or listen to a live webcast on the company's investor relations page. A replay will be available online for 14 days, and telephonic replays will be accessible until August 16, 2022. ViewRay specializes in MR-guided radiation therapy systems, particularly the MRIdian system, designed to enhance treatment in radiation oncology.
ViewRay, Inc. (Nasdaq: VRAY) announced that the VA Ann Arbor Healthcare System has selected its MRIdian MRI-guided radiation therapy system to enhance cancer treatment services at the Lieutenant Colonel Charles S. Kettles VA Medical Center. This addition allows the facility to provide advanced radiation therapy for various cancers, enhancing care for veterans in the region. The MRIdian system enables precise treatment by utilizing real-time MRI visualization, improving the safety and effectiveness of radiation therapy. Over 22,000 patients have been treated using MRIdian worldwide.
ViewRay, Inc. (NASDAQ: VRAY) announced that Shin-Matsudo Central General Hospital in Japan has acquired a MRIdian MRI-guided radiation therapy system. This marks the third installation of the MRIdian system in Japan, aimed at addressing a growing cancer patient population in the Toukatsu area. The system will enhance treatment precision for cancers such as pancreas and prostate, utilizing advanced techniques including stereotactic body radiation therapy (SBRT). Patient treatments are expected to commence in early Fall 2023.
ViewRay, Inc. (Nasdaq: VRAY) announces that Henry Ford Health is the first center globally to complete patient treatments using the new MRIdian A3i System. This system enhances clinical workflow by reducing treatment times and enabling advanced brain treatment capabilities. Features include automated contouring and multi-plane tracking, improving treatment precision. Over 21,000 patients have benefited from MRIdian's technology, and 50 systems are operational worldwide. Henry Ford's leadership in MR-guided radiation therapy continues as they pioneer brain treatment with the MRIdian A3i.
ViewRay, Inc. (Nasdaq: VRAY) has released a retrospective study highlighting the effectiveness of its MRIdian system for treating ultracentral and central lung lesions with minimal toxicity. Presented at the ESTRO 2022 conference, the study indicates that MRI-guided stereotactic body radiation therapy (SBRT) resulted in excellent oncologic outcomes in 29 patients, with only one Grade 3 toxicity recorded. This stands in contrast to previous non-MRI studies that reported high toxicity rates. The MRIdian system's real-time tracking and automated beam control enhance treatment precision while minimizing damage to surrounding tissues.
ViewRay, Inc. (Nasdaq: VRAY) celebrates 10 years of pioneering real-time tissue tracking with automatic beam gating. At the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) from May 6-10, 2022, the MRIdian MRI-guided radiation therapy system will showcase nearly 40 presentations on its clinical applications. Key features of the MRIdian A3i will be presented during a symposium on May 7, emphasizing its innovative treatment capabilities. Over 21,000 patients have benefited from MRIdian, which remains the only system offering this technology.
ViewRay, Inc. (Nasdaq: VRAY) reported first-quarter 2022 revenue of approximately $18.9 million, up from $15.5 million in the same quarter of 2021. The company received seven new orders for MRIdian systems totaling $40.9 million, increasing total backlog to $330.9 million. Despite a net loss of $25.8 million or $(0.14) per share, a slight improvement from $26.7 million or $(0.17) per share the previous year, ViewRay has $183.2 million in cash. The company maintains its 2022 revenue guidance of $84 million to $104 million.
ViewRay, Inc. (NASDAQ: VRAY) announced the purchase of its MRIdian MRI-guided radiation therapy system by UCI Health for the new Chao Family Comprehensive Cancer Center, set to open in late 2023. This center is part of a $1.3 billion medical facility being built in Orange County. The MRIdian system offers advanced cancer treatment by providing real-time MR imaging and adaptive therapy, allowing targeted treatment while minimizing damage to healthy tissues. With over 21,000 patients treated using MRIdian, this innovative technology enhances treatment options for complex cases in the region.
ViewRay, Inc. (Nasdaq: VRAY) announced a conference call scheduled for May 5, 2022, at 4:30 p.m. ET to discuss its first-quarter financial results. The call can be accessed domestically at (844) 277-1426 and internationally at (336) 525-7129. A live webcast will be available on the company's investor relations site and will remain accessible for 14 days after the event. ViewRay specializes in innovative MR-guided radiation therapy systems, focusing on advanced radiation oncology.
